|
|
Icu Medical Inc (NASDAQ: ICUI) |
|
Price: $134.4500
$-2.34 
-1.711%
|
| Day's High:
| $138.05
| Week Perf:
| 2.35 %
|
| Day's Low: |
$ 133.74 |
30 Day Perf: |
-2.78 % |
| Volume (M): |
163 |
52 Wk High: |
$ 196.26 |
| Volume (M$): |
$ 21,902 |
52 Wk Avg: |
$151.60 |
| Open: |
$137.60 |
52 Wk Low: |
$111.24 |
|
|
| Market Capitalization (Millions $) |
3,299 |
| Shares
Outstanding (Millions) |
25 |
| Employees |
6,700 |
| Revenues (TTM) (Millions $) |
2,420 |
| Net Income (TTM) (Millions $) |
-28 |
| Cash Flow (TTM) (Millions $) |
38 |
| Capital Exp. (TTM) (Millions $) |
88 |
Icu Medical Inc
ICU Medical Inc. is a global medical device company that specializes in designing, manufacturing, and selling a broad range of products for critical care and infusion therapy applications. The company was founded in 1984 by Dr. George Lopez and is headquartered in San Clemente, California.
ICU Medical produces a wide range of medical equipment for the healthcare industry, including needle-free systems, closed system transfer devices, catheters, and other accessories that are used in hospitals, clinics, and other healthcare facilities worldwide. The company's product portfolio is focused on intravenous (IV) infusion and critical care therapy, with a particular emphasis on medication delivery systems.
ICU Medical's products are designed to help reduce the risk of infection, contamination, and medication errors, while also improving patient safety, comfort, and convenience. The company's products are used in a variety of medical settings, including operating rooms, intensive care units, emergency departments, and ambulatory care centers.
One of ICU Medical's most innovative products is the "Clave" needle-free injection system, which was first introduced in 2000. The Clave system enables healthcare professionals to safely administer medications, fluids, and blood products to patients without the use of a needle, reducing the risk of needlestick injuries and infection. The Clave system is now used in hospitals and healthcare facilities worldwide and has become a standard of care in many healthcare settings.
Another key product offering from ICU Medical is the ChemoClave system, a closed system transfer device that allows for safe handling of hazardous drugs during chemotherapy infusion. This system helps to protect healthcare workers from exposure to potentially harmful substances, while also reducing the risk of contamination and environmental exposure.
In addition to its core product offerings, ICU Medical also offers a range of complementary services, including clinical education and training, technical support, and consulting services. The company's customer base includes a wide range of healthcare providers, including hospitals, ambulatory care centers, dialysis centers, and infusion therapy providers.
ICU Medical is committed to innovation, quality, and safety, and has received numerous certifications, awards, and recognition for its products and services. The company is focused on continuing to develop and improve its product offerings to help healthcare providers deliver the highest quality care to their patients.
Company Address: 951 Calle Amanecer San Clemente 92673 CA
Company Phone Number: 366-2183 Stock Exchange / Ticker: NASDAQ ICUI
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Icu Medical Inc
Investors in ICU Medical Inc may be concerned after the company reported losses in the first quarter of 2024 due to deteriorating demand. The medical equipment and supplies sector as a whole experienced a top-line gain, further highlighting ICU Medical Inc's underperformance.
In the first quarter of 2024, ICU Medical Inc saw a decrease in revenue by -0.423% to $566.24 million, with a loss per share of $-1.63 compared to $-0.41 per share in the same period last year. The company's net loss also significantly increased to $-39.471 million from $-9.812 million a year ago.
|
| Icu Medical Inc
Despite some challenges, ICU Medical Inc. continues to show strength and resilience in the stock market. While there were some decreases in income per share and bottom-line numbers, the company also saw growth in revenue and improvements in sales. With a focus on improving sales and a net margin of 10.38%, ICU Medical Inc. is working hard to drive success in the medical equipment & supplies industry.
The company's shift in focus towards improving sales has led to positive results, with a slight increase in revenue and a decrease in loss per share. ICU Medical Inc. is determined to navigate any obstacles and continue to thrive in the market.
|
| Icu Medical Inc
Article:
As the fiscal third quarter of 2023 came to a close, Icu Medical Inc found itself in a position of profitability despite facing a significant decline in revenue. Despite this challenge, the company managed to turn things around by showcasing impressive earnings per share (EPS) of $0.30, contrasting the previous year's shortfall of $-0.55 per share.
During this period, Icu Medical Inc witnessed a -7.516% decrease in revenue, with figures dropping to $552.92 million from $597.86 million in the prior year's Q3. This deterioration in revenue starkly contrasts with the overall performance of the Medical Equipment & Supplies sector, which saw a top-line gain during the same period.
|
| Icu Medical Inc
Declining Business Performance Raises Concern for Icu Medical Inc Investors
In the most recent fiscal period, Icu Medical Inc, a renowned player in the Medical Equipment & Supplies industry, faced a considerable decline in its business performance. This downward trend has resulted in losses, impacting both revenue and earnings per share negatively.
The company's revenue dropped by -2.26% to $548.33 million, compared to the previous reporting period. Furthermore, the loss per share increased from $-0.31 to $-0.41 in the same period. This decline in the top-line growth is in stark contrast to the Medical Equipment & Supplies industry, which experienced a revenue rise during the same period.
|
| Icu Medical Inc
As the first quarter of 2023 draws to a close, Icu Medical Inc, a leading provider of medical devices, reported a disappointing return on assets (ROA) of 1.53%. This figure is well below the company's average ROA of 3.95%, indicating that the company is struggling to generate profits from its assets.
Despite the net income deteriorating, Icu Medical Inc has managed to improve ROA from the fourth quarter of 2022. However, this improvement is not enough to impress investors, as 115 healthcare companies have a higher return on assets than Icu Medical. This suggests that the company is lagging behind its competitors in terms of profitability and operational efficiency.
|
| Per Share |
Current |
| Earnings (TTM) |
-3.83 $ |
| Revenues (TTM) |
98.61 $
|
| Cash Flow (TTM) |
1.56 $ |
| Cash |
-
|
| Book Value |
81 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.83 $
|
| Revenues (TTM) |
98.61 $ |
| Cash Flow (TTM) |
1.56 $ |
| Cash |
-
|
| Book Value |
81 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Infusion Consumables |
|
 44.07 % |
of total Revenue |
| Infusion Systems |
|
27.53 % |
of total Revenue |
| Vital Care |
|
28.5 % |
of total Revenue |
| UNITED STATES |
|
64.27 % |
of total Revenue |
| EMEA |
|
15.84 % |
of total Revenue |
| Asia Pacific |
|
9.83 % |
of total Revenue |
| Other foreign countries |
|
10.16 % |
of total Revenue |
| |
On February 27 2024 the Icu Medical Inc provided following guidance
ICU Medical Inc., a prominent company specializing in the creation, production, and distribution of cutting-edge medical devices, has recently disclosed its financial outcomes for the fourth quarter of 2023, which concluded on December 31st. The company, listed on the Nasdaq stock exchange under the ticker symbol ICUI, remains at the forefront of the medical technology industry.
Taking into account the results of the fourth quarter of 2023, ICU Medical Inc. has determined its financial forecast for the fiscal year 2024. The company's estimations for the upcoming year, presented on February 27th, 2024, reflect its commitment to continued growth and success in the medical equipment sector. With a focus ...
|
|
|
